Clay Siegall is the CEO of Seattle Genetics, a biotechnology company that specializes in research on treatments for cancer. Siegall co-founded the company in 1998 and has been the CEO since 2002. Currently, he also serves as president and chairman of the board of the company. Under his leadership, the company has made remarkable progress in cancer research as well as innovative therapies for cancer patients. Siegall’s honest desire to help cancer patients has driven him to diligently carry out extensive research and implement the most suitable research developments.
Before he co-founded Seattle Genetics, Clay worked as a Senior Research Investigator at the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. From 1988 to 1991, he was with National Cancer Institute, National Institutes of Health where he was a Staff Fellow and Biotechnology Fellow. Dr. Siegall also served a Non-Executive Director of Mirna Therapeutics, a biotechnology company dedicated to the development and commercialization of microRNA (miRNA) therapeutics, from January 2013 to December 2016. Clay is also a member of the Board of Scientific Counselors for the Cancer Treatment Research Foundation. Clay holds a Ph.D. in Genetics from George Washington University as well as a Bachelor’s Degree in Zoology from the University of Maryland.
Siegall is a renowned researcher and currently holds more than 10 patents. Additionally, he serves in editorial boards of some scientific journals where he offers mentorship and guidance to other scientists. Clay has published several scientific papers, and he continues to share his rich knowledge with the medical and scientific communities.
Awards and Recognitions
Due to his passion and incredible contributions to the medical and scientific communities, Clay has received several awards and recognitions. In 2013, he received the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. Additionally, he was named the Pacific Northwest Ernst & Young Entrepreneur of the Year. He also received the Pierce Award in 1995 for his contribution in the field of targeted toxins.
Clay Siegall is undoubtedly a brilliant leader who has made a remarkable impact in the medical field. With his passion and commitment, Clay has pushed Seattle Genetics to high levels in research developments. His innovative ideas and continued investment in futuristic technology have led to immense success of the company. Siegall is simply unstoppable and he continues to offer valuable solutions to cancer patients worldwide.